Company intelligence / Profile preview

Navotek Medical

Yokneam Illit/Yokneam Industrial Park, Israelil.linkedin.com ↗

Ownership: Private
Employees: ~29
Development stage: Commercial

Overview

The company’s flagship product, the RealEye System—an add-on to linear accelerators for radiation therapy—received FDA clearance in March 2011. It enables real-time monitoring of tumor position during treatment to improve accuracy and minimize healthy tissue exposure. The system reduces reliance on anatomical imaging and can lower nontherapeutic radiation exposure. Clinical results are not detailed but regulatory clearance indicates safety and efficacy sufficient for market entry.

Therapeutic areas: OncologyNeurology
Modalities: Device
Industry: Therapeutic Medical Devices

Partnerships

No major pharmaceutical or biotech partnerships publicly listed.

Beyond the preview

Go deeper on Navotek Medical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Navotek Medical.

Explore the full profile